Anti-SLN monoclonal antibody

Pre-made anti-SLN monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to SLN/SLN products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1752-Ab-1/ GM-Tg-hg-IP1752-Ab-2Anti-Human SLN monoclonal antibodyHuman
GM-Tg-rg-IP1752-Ab-1/ GM-Tg-rg-IP1752-Ab-2Anti-Rat SLN monoclonal antibodyRat
GM-Tg-mg-IP1752-Ab-1/ GM-Tg-mg-IP1752-Ab-2Anti-Mouse SLN monoclonal antibodyMouse
GM-Tg-cynog-IP1752-Ab-1/ GM-Tg-cynog-IP1752-Ab-2Anti-Cynomolgus/ Rhesus macaque SLN monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1752-Ab-1/ GM-Tg-felg-IP1752-Ab-2Anti-Feline SLN monoclonal antibodyFeline
GM-Tg-cang-IP1752-Ab-1/ GM-Tg-cang-IP1752-Ab-2Anti-Canine SLN monoclonal antibodyCanine
GM-Tg-bovg-IP1752-Ab-1/ GM-Tg-bovg-IP1752-Ab-2Anti-Bovine SLN monoclonal antibodyBovine
GM-Tg-equg-IP1752-Ab-1/ GM-Tg-equg-IP1752-Ab-2Anti-Equine SLN monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1752-Ab-1/ GM-Tg-hg-IP1752-Ab-2; GM-Tg-rg-IP1752-Ab-1/ GM-Tg-rg-IP1752-Ab-2;
GM-Tg-mg-IP1752-Ab-1/ GM-Tg-mg-IP1752-Ab-2; GM-Tg-cynog-IP1752-Ab-1/ GM-Tg-cynog-IP1752-Ab-2;
GM-Tg-felg-IP1752-Ab-1/ GM-Tg-felg-IP1752-Ab-2; GM-Tg-cang-IP1752-Ab-1/ GM-Tg-cang-IP1752-Ab-2;
GM-Tg-bovg-IP1752-Ab-1/ GM-Tg-bovg-IP1752-Ab-2; GM-Tg-equg-IP1752-Ab-1/ GM-Tg-equg-IP1752-Ab-2
Products NameAnti-SLN monoclonal antibody
Formatmab
Target NameSLN
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-SLN monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1752-Ag-1Recombinant multi-species SARCO/ SLN protein


    Target information

    Target IDGM-IP1752
    Target NameSLN
    Gene ID6588,66402,367086,100424360,100686810,101088269,100296455,106783340
    Gene Symbol and Synonyms2310045A07Rik,SLN
    Uniprot AccessionO00631,Q6SLE7
    Uniprot Entry NameSARCO_HUMAN,SARCO_RAT
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000170290
    Target ClassificationN/A

    The target: SLN, gene name: SLN, also named as . Sarcoplasmic reticulum Ca(2+)-ATPases are transmembrane proteins that catalyze the ATP-dependent transport of Ca(2+) from the cytosol into the lumen of the sarcoplasmic reticulum in muscle cells. This gene encodes a small proteolipid that regulates several sarcoplasmic reticulum Ca(2+)-ATPases. The transmembrane protein interacts with Ca(2+)-ATPases and reduces the accumulation of Ca(2+) in the sarcoplasmic reticulum without affecting the rate of ATP hydrolysis. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.